Reckitt Benckiser (LON:RB) has been given a GBX 7,000 ($94.95) target price by analysts at JPMorgan Chase in a research note issued to investors on Friday, May 11th. The firm presently has a “buy” rating on the stock. JPMorgan Chase’s target price would suggest a potential upside of 17.65% from the company’s previous close.
RB has been the subject of a number of other research reports. UBS set a GBX 7,000 ($94.95) price target on Reckitt Benckiser and gave the stock a “neutral” rating in a research report on Thursday, January 11th. Liberum Capital reiterated a “buy” rating and set a GBX 8,000 ($108.52) target price on shares of Reckitt Benckiser in a research report on Monday, January 15th. Citigroup set a GBX 7,900 ($107.16) price target on Reckitt Benckiser and gave the company a “buy” rating in a report on Tuesday, January 16th. Berenberg Bank set a GBX 7,900 ($107.16) price target on Reckitt Benckiser and gave the company a “buy” rating in a report on Friday, January 19th. Finally, Barclays set a GBX 6,700 ($90.88) price objective on Reckitt Benckiser and gave the company a “neutral” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of GBX 7,045.22 ($95.57).
Reckitt Benckiser traded up GBX 47 ($0.64), reaching GBX 5,950 ($80.71), during trading on Friday, MarketBeat Ratings reports. The stock had a trading volume of 2,259,930 shares, compared to its average volume of 1,720,000. Reckitt Benckiser has a 52 week low of GBX 5,562 ($75.45) and a 52 week high of GBX 8,110.43 ($110.02).
In other Reckitt Benckiser news, insider Rakesh Kapoor sold 120,000 shares of Reckitt Benckiser stock in a transaction dated Friday, May 4th. The stock was sold at an average price of GBX 5,576 ($75.64), for a total transaction of £6,691,200 ($9,076,505.70).
Reckitt Benckiser Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.